In pediatric pharmacokinetics, how does maturation affect drug clearance and what covariate is commonly included in a PK model?

• A. Clearance matures with age; include a maturation function (e.g., sigmoid Emax) with weight-based allometry.
• B. Clearance is the same as adults; no maturation term is needed.
• C. Clearance decreases with age.
• D. Only sex influences clearance.

Answer: (A)

In pediatric pharmacokinetics, clearance changes as organ systems mature. Neonates have immature liver and kidney function, so they typically clear drugs more slowly than adults, and clearance increases as children grow toward adult levels. To capture this in models, we include a maturation function for clearance that describes how ontogeny alters clearance with age. A common choice is a sigmoid Emax (Hill-type) function, which starts low in early life, rises steeply during the period of rapid maturation, and then levels off as maturation closes in on adult values.

At the same time, body size matters, so clearance is typically scaled by weight using allometry. The standard approach combines both ideas: clearance scales with weight (often with an exponent around 0.75) and is multiplied by a maturation function that depends on age. This allows the model to predict clearance across a wide pediatric age range—from neonates through older children—by accounting for both growth and maturational development.

So the best answer reflects that clearance matures with age and is commonly modeled with a maturation function (such as sigmoid Emax) alongside weight-based allometric scaling. Other options ignore maturation, imply decreasing clearance with age, or rely only on sex, which does not fit the established understanding of ontogeny in drug clearance.